PTC Therapeutics Inc 2025 SR
The report highlights PTC Therapeutics' corporate social responsibility achievements and operational milestones in 2025. Key highlights include the global launch of Sephience for phenylketonuria and advancements in its RNA Splicing and Inflammation & Ferroptosis scientific platforms. The company also focused on employee well-being, achieving a voluntary turnover rate below 4% and receiving multiple workplace culture awards. Additionally, PTC Therapeutics demonstrated environmental responsibility by designing its New Jersey headquarters to meet LEED Gold standards and sourcing all electricity for the facility from renewable arrangements.
Company: PTC Therapeutics Inc
Sector: Health Care
Country: United States
Year: 2025
Type: SR
Pages: 61
PTC Therapeutics Inc
Corporate Social Responsibility Report
The report highlights PTC Therapeutics' corporate social responsibility achievements and operational milestones in 2025. Key highlights include the global launch of Sephience for phenylketonuria and advancements in its RNA Splicing and Inflammation & Ferroptosis scientific platforms. The company also focused on employee well-being, achieving a voluntary turnover rate below 4% and receiving multiple workplace culture awards. Additionally, PTC Therapeutics demonstrated environmental responsibility by designing its New Jersey headquarters to meet LEED Gold standards and sourcing all electricity for the facility from renewable arrangements.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Employees